Skip to main content

ADM Tronics to Participate at Lytham Partners Summer 2021 Investor Conference

Written by Customer Service on . Posted in Public Companies.

Northvale, NJ, June 07, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — ADM Tronics Unlimited, Inc. (OTCQB: ADMT) announced today that it will be participating at the Lytham Partners Summer 2021 Investor Conference.   Andre DiMino, President of ADMT, will be available for virtual one-on-one meetings throughout the event, which runs from June 14, 2021 through June 16, 2021. To arrange a meeting, contact a Lytham Partners representative at: 1×1@lythampartners.com or register at http://www.lythampartners.com/summer2021invreg

“We look forward to participating in the Lytham Partners Summer 2021 Investor Conference and discussing our company’s activities and developments during the one-on-one meetings,” stated DiMino.

ADMT designs, develops and manufactures electronic medical device technologies at its FDA-Registered and ISO-13485 Certified Medical Device Manufacturing Facility in Northvale, NJ.  ADMT has extensive experience in the development of all FDA classes of medical devices with particular emphasis on non-invasive, electronic therapeutic modalities.  The Company has a pipeline of proprietary medical devices in various stages of development.

In addition to its own medical technology developments, the Company is a one-stop source for complete design, engineering, regulatory and manufacturing services, specifically related to US and international electronic medical device development.  Its capability in bringing a medical device from the conceptual stage, through design, development and regulatory stages into production, all in-house, differentiates ADMT from firms supplying only portions of those services. 

ADMT welcomes inquiries for its medical device services via the ADMT website – www.admtronics.com.

To receive email updates directly from the Company, fill in the form at the bottom of this page: https://admtronics.com/investor-relations/

About ADMT

ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products.  Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house.  ADMT has three areas of activity: Proprietary Medical Devices; Medical Device Design, Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly Formulations from its headquarters, laboratories, and FDA-Registered medical device manufacturing operations.  ADMT’s multi-disciplinary team of engineers, researchers, and technologists utilize advanced technology infrastructure for R&D and commercialization of diversified technologies. admtronics.com.
 
Except for historical information contained herein, the matters set forth in this news release are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance.  Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations.  Factors that could contribute to such differences include those described from time to time in ADMT’s SEC filings, news releases, and other communications. The Company assumes no obligation to update the information contained in this news release.

Andre DiMino
201-767-6040
andre@admtronics.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.